mRNA Size Analysis Service
In the rapidly evolving landscape of therapeutic nucleic acids, the mRNA size analysis service stands as a cornerstone of structural characterization. As a critical component of the mRNA-based vaccine development platform at CD BioGlyco, this service ensures the precise determination of transcript length, integrity, and purity. Since the size of messenger RNA (mRNA) directly correlates with its ability to encode complete proteins, any deviation compromises the efficacy and safety of the final therapeutic product. Our specialized analysis provides the high-resolution data necessary to confirm that the drug substance meets the stringent specifications.
At CD BioGlyco, our service scope is meticulously designed to support the entire lifecycle of mRNA development, from initial in vitro transcription (IVT) optimization to final batch release. Under the umbrella of mRNA structural characterization, we offer a comprehensive analysis that goes beyond simple length measurement. Our capabilities include:
By integrating these methods into the therapeutic nucleic acid development platform, we help researchers navigate the complexities of mRNA structural variations, ensuring that every batch is characterized with the utmost precision.
Upon receiving the mRNA samples, our team performs an initial quality check to assess concentration and basic purity. This stage ensures that the sample matrix is compatible with our high-resolution instruments.
Samples are prepared using RNA-specific buffers and denaturing agents. For CGE, samples are often heat-denatured to resolve secondary structures, ensuring that separation is strictly dependent on the primary nucleotide length.
In CGE, molecules migrate through a polymer network under a high-voltage electric field. In the SEC, the mRNA is separated through wide-pore columns specifically selected for large biomolecules.
LIF provides high-sensitivity fluorescence signals for CGE, while the MALS detector captures light scattering at multiple angles to calculate the absolute mass of the species in real-time.
Our bioinformaticians use advanced software to convert raw signals into sizing data. This involves comparing migration times against internal standards for CGE.
We provide electropherograms, molar mass distributions, and a summary of the percentage of full-length mRNA. Our experts are available to discuss the results and suggest optimizations for your development process.
DoI: 10.1101/2022.02.14.480356
Journal: bioRxiv
Published: 2022
Results: This study develops an automated, high-throughput workflow for rapid characterization and sequence mapping of large RNAs and mRNA therapeutics. The workflow combines partial RNase T1 digestion with high-resolution liquid chromatography-tandem mass spectrometry (LC-MS/MS) and automated oligoribonucleotide identification via MS/MS spectra. Controlled partial digestion generates longer, uniquely mappable fragments, overcoming limitations of complete digestion. The method achieves >80% sequence coverage (up to 95.9% for eGFP mRNA without poly-A tail) in a single 90-minute analysis, including chemically modified mRNAs. It demonstrates specificity, reproducibility, and the ability to detect RNA impurities. This tool supports identity testing, sequence validation, and impurity analysis, addressing critical needs for mRNA therapeutic quality control.
Fig.1 mRNA sequence mapping. (Vanhinsbergh, et al., 2022)
Vaccine Development and Quality Control
Size analysis is essential for verifying that mRNA vaccines contain the full-length sequence required to produce the target antigen. Our services ensure batch-to-batch consistency during the manufacturing process.
Gene Therapy Research
We provide the high-resolution data needed to confirm that the therapeutic mRNA reaches the target length without significant fragmentation.
IVT Process Optimization
Researchers use our sizing data to evaluate the impact of different T7 RNA polymerase variants or nucleotide concentrations on transcription efficiency, minimizing the production of shortened or truncated mRNA species.
RNA Interference and Small RNA Characterization
While focused on large mRNA, our platforms are versatile enough to characterize the size and purity of smaller therapeutic RNAs, ensuring that the processing of precursor molecules is accurate and efficient.
Low Sample Requirements
Our microfluidic and capillary-based systems are designed to operate with minimal sample volumes, preserving your precious therapeutic mRNA for further downstream applications and functional assays.
Scalable High-Throughput Processing
CD BioGlyco features automated systems capable of handling large batches of samples simultaneously, significantly reducing turnaround times for projects involving extensive library screening or large-scale manufacturing support.
Rigorous Quality Management
All analyses are conducted in a controlled environment following stringent protocols, ensuring that the data generated meets the high standards required for research.
Expert Interpretive Support Services
Beyond providing raw data, our PhD-level scientists offer in-depth interpretation of sizing results, helping you understand the structural implications of the data for your specific mRNA vaccine candidate.
The resolution provided by CD BioGlyco's sizing service was instrumental in identifying a persistent truncation issue in our IVT process. Their team helped us interpret the electropherograms, leading to a 30% increase in our full-length mRNA yield.
— Dr. L.S., Senior Scientist
We were particularly impressed with the SEC-MALS data. The report was detailed and professionally presented.
— A.G., Director of Analytical Development
The ability to characterize very long saRNA transcripts with such precision is a testament to their advanced platform. We will certainly continue our partnership for future projects.
— A.T., Principal Investigator
CD BioGlyco provides a world-class mRNA size analysis service that serves as a vital pillar for mRNA structural characterization. By combining cutting-edge CGE and SEC-MALS technologies with deep scientific expertise, we ensure that your mRNA therapeutics are sized with precision, purity, and absolute accuracy. Please feel free to contact us to discuss your project or request a detailed quotation.
Reference
